Trial Profile
A Randomized Controlled Trial of L-DEP as an Initial Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Etoposide (Primary) ; Methylprednisolone (Primary) ; Pegaspargase (Primary) ; Dexamethasone
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 29 Sep 2016 New trial record